News

Following its initial review of a supplemental new drug application for Lexapro (excitalopram oxalate) in social anxiety disorder, the FDA has determined the application not approvable and has

The study is designed to evaluate the safety and immunogenicity of Fluviral in healthy adults and has been expanded from 300 to 1,000 subjects. It is intended to

“A key aspect of anthrax spore biology concerns the germination process through which the dormant spore becomes a reproductive, disease-causing bacterium,” explained Al Claiborne, the study’s principal investigator.

Biovail’s original application for an extended-release, once-daily formulation of tramadol hydrochloride, intended for the treatment of moderate and moderately severe pain, was submitted in December 2003. Additional clinical

The results, published in the current issue of General Hospital Psychiatry, also suggest that it may be possible to reduce by as much as 40% the time severely

Aeras, a US non-profit organization and Statens Serum Institut (SSI), a company owned by the Danish government, will form a joint product development team and Aeras will provide

In March 2005, Barr confirmed that Kos had filed a motion in a US District Court seeking to prevent Barr from launching generic versions of Niaspan, a cholesterol-lowering

As a result of its scheduled interim safety analysis, the independent data monitoring committee (DMC) recommended the continuation of the clinical trial, named GENASIS, which is designed to

The collaboration aims to develop improved interferon alpha protein therapeutics to treat hepatitis C virus (HCV) and hepatitis B virus (HBV) infections. Maxygen and Roche are currently completing